Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017

Publisher Name :
Date: 27-Jun-2017
No. of pages: 1430
Inquire Before Buying

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 102, 55, 1, 5, 158, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 10, 15, 1, 32 and 9 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017

Table of Contents
Table of Contents 2
Introduction 10
Glioblastoma Multiforme (GBM) - Overview 11
Glioblastoma Multiforme (GBM) - Therapeutics Development 12
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 57
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 83
Glioblastoma Multiforme (GBM) - Drug Profiles 181
Glioblastoma Multiforme (GBM) - Dormant Projects 1365
Glioblastoma Multiforme (GBM) - Discontinued Products 1375
Glioblastoma Multiforme (GBM) - Product Development Milestones 1377
Appendix 1388

List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by apceth Biopharma GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Autotelic Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Beactica AB, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Berg LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cellmid Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlioPharma ApS, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison China MediTech Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Insys Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ipsen SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Juno Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by NanoCarrier Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nektar Therapeutics, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ovensa Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peptomyc SL, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Phoenix Biotechnology Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by PTC Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Systimmune Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..6), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..7), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..8), H1 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..9), H1 2017
Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2017
Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2019-2024
    Published: 13-Nov-2019        Price: US 3660 Onwards        Pages: 150
    According to this study, over the next five years the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market will register a 22.2% CAGR in terms of revenue, the global market size will reach US$ 16970 million by 2024, from US$ 7617.6 million in 2019. In particular, this report presents the global revenue market share of key companies in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) business, shared in Chapter 3. This report presents a comprehensive overvi......
  • Global Castration-Resistant Prostate Cancer (CRPC) /HRPCA Therapeutics Market Professional Survey Report 2019
    Published: 06-Nov-2019        Price: US 3500 Onwards        Pages: 109
    The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market si......
  • Global Cancer Pain Therapeutics Industry Market Research Report
    Published: 31-Oct-2019        Price: US 2960 Onwards        Pages: 107
    The Cancer Pain Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Cancer Pain Therapeutics industrial chain, this report mainly elaborates the definition, types, applications and major players of Cancer Pain Therapeutics market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise p......
  • 2017-2025 World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 31-Oct-2019        Price: US 2800 Onwards        Pages: 96
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Castration-Resistant Prostate Cancer (CR......
  • Global Actinic Keratosis Treatment Market Growth (Status and Outlook) 2019-2024
    Published: 30-Oct-2019        Price: US 3660 Onwards        Pages: 115
    According to this study, over the next five years the Actinic Keratosis Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Actinic Keratosis Treatment business, shared in Chapter 3. This report presents a comprehensive overview, market shares and growth opportunities of Actinic Keratosis Treatment......
  • 2017-2025 World Breast Cancer Monoclonal Antibodies Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 29-Oct-2019        Price: US 2800 Onwards        Pages: 142
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Breast Cancer Monoclonal Antibodies , co......
  • Global Kaposi Sarcoma Market Professional Survey Report 2019
    Published: 29-Oct-2019        Price: US 3500 Onwards        Pages: 106
    The global Kaposi Sarcoma market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Kaposi Sarcoma volume and value at global level, regional level and company level. From a global perspective, this report represents overall Kaposi Sarcoma market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and......
  • Global T-Cell Immunotherapy Market Professional Survey Report 2019
    Published: 24-Oct-2019        Price: US 3500 Onwards        Pages: 104
    The global T-Cell Immunotherapy market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on T-Cell Immunotherapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall T-Cell Immunotherapy market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consu......
  • Global Small Cell Lung Cancer Therapeutics Industry Market Research Report
    Published: 17-Oct-2019        Price: US 2960 Onwards        Pages: 115
    The Small Cell Lung Cancer Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Small Cell Lung Cancer Therapeutics industrial chain, this report mainly elaborates the definition, types, applications and major players of Small Cell Lung Cancer Therapeutics market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs